Biethahn S, Alves F, Wilde S, Hiddemann W, Spiekermann K
Department of Hematology and Oncology, University of Göttingen, Germany.
Exp Hematol. 1999 May;27(5):885-94. doi: 10.1016/s0301-472x(99)00017-x.
Acute myelogenous leukemia (AML) is characterized by the malignant transformation of hematopoietic stem cells leading to dysregulated growth and differentiation of myeloid cells. Normally, proliferation and differentiation of myeloid cells are regulated by cytokines such as granulocyte colony-stimulating factor (G-CSF) or granulocyte-macrophage colony-stimulating factor (GM-CSF). Abnormal signaling of the signal transduction pathway from the cytokine receptors via Janus kinases (JAKs) and signal transducers and activators of transcription (STATs) might be involved in the pathogenesis of AML. We examined whether an abnormal expression of one of the four JAKs, STAT1, STAT3, STAT5, or the tyrosine phosphatase SHP-1, a negative regulator of this pathway, is associated with malignant transformation in AML. Analysis of the expression of proteins of the JAK/STAT pathway in normal myeloid cells at three stages of maturation revealed a strong expression of all proteins in CD34+ cells, whereas the level of the proteins was significantly lower in granulocytic precursors and mature neutrophils. Furthermore, during maturation the relation of the isoforms of STAT1 and STAT3 changed from predominantly alpha to predominantly beta. Leukemic blast cells from 25 patients and 12 cell lines showed a high level of STAT proteins and SHP-1, whereas a deficiency of at least one of the four JAKs was found in 10 of 25 patients. In primary AML blast cells a deficiency of three JAKs was more common in patients with an abnormal karyotype. In addition, a lack of JAK2 and Tyk2 protein was strongly associated with the FAB M2 phenotype. The proliferation rate in response to GM-CSF available in a small number of patients appears to be related to the JAK2 expression. Our data suggest that the degree of expression of G-CSF/GM-CSF receptor-associated proteins of the JAK/STAT pathway in normal myeloid cells is related with their clonogenic potential. STAT3 appears to be involved in early differentiation. Similar to CD34+ cells, it is likely that the high levels of STATs and SHP-1 found in leukemic cells reflects their proliferative activity, whereas a lack of members of the JAK family might lead to an inability to proliferate in response to G-CSF/GM-CSF described in a considerable percentage of AML blasts.
急性髓系白血病(AML)的特征是造血干细胞发生恶性转化,导致髓系细胞生长和分化失调。正常情况下,髓系细胞的增殖和分化受细胞因子调控,如粒细胞集落刺激因子(G-CSF)或粒细胞-巨噬细胞集落刺激因子(GM-CSF)。细胞因子受体通过Janus激酶(JAKs)以及信号转导和转录激活因子(STATs)的信号转导通路异常信号可能参与了AML的发病机制。我们研究了四种JAKs之一、STAT1、STAT3、STAT5或该通路的负调节因子酪氨酸磷酸酶SHP-1的异常表达是否与AML中的恶性转化相关。对正常髓系细胞成熟三个阶段JAK/STAT通路蛋白表达的分析显示,所有蛋白在CD34+细胞中均有强烈表达,而在粒细胞前体和成熟中性粒细胞中蛋白水平显著降低。此外,在成熟过程中,STAT1和STAT3异构体的关系从主要为α型转变为主要为β型。来自25例患者的白血病原始细胞和12个细胞系显示STAT蛋白和SHP-1水平较高,而25例患者中有10例发现至少一种JAKs缺乏。在原发性AML原始细胞中,三种JAKs缺乏在核型异常的患者中更为常见。此外,JAK2和Tyk2蛋白的缺乏与FAB M2表型密切相关。少数患者中对GM-CSF的增殖反应率似乎与JAK2表达有关。我们的数据表明,正常髓系细胞中JAK/STAT通路的G-CSF/GM-CSF受体相关蛋白的表达程度与其克隆形成潜力有关。STAT3似乎参与早期分化。与CD34+细胞类似,白血病细胞中发现的高水平STATs和SHP-1可能反映了它们的增殖活性,而JAK家族成员的缺乏可能导致相当比例的AML原始细胞无法对G-CSF/GM-CSF作出增殖反应。